JOP20200002A1 - شدفة Fab جديدة لجسم مضاد ضد CEACAM5 البشري - Google Patents
شدفة Fab جديدة لجسم مضاد ضد CEACAM5 البشريInfo
- Publication number
- JOP20200002A1 JOP20200002A1 JOP/2020/0002A JOP20200002A JOP20200002A1 JO P20200002 A1 JOP20200002 A1 JO P20200002A1 JO P20200002 A JOP20200002 A JO P20200002A JO P20200002 A1 JOP20200002 A1 JO P20200002A1
- Authority
- JO
- Jordan
- Prior art keywords
- fab fragment
- cancer
- human ceacam5
- antibody fab
- ceacam5 antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
شدفة Fab جديدة لجسم مضاد ضد CEACAM5 البشري الملخص يزود هذا الاختراع شدفة Fab لجسم مضاد ضد CEACAM5 بشري من المتوقع أن تكون مفيدة في تشخيص السرطان، وخاصة تشخيص سرطان القولون والمستقيم، سرطان الثدي، سرطان الرئة، سرطان الغدة الدرقية، أو سرطان ناتج عن نقائلها وطريقة تشخيص باستخدام متقارن يشتمل على شدفة Fab. ويزود الاختراع الحالي شدفة Fab لجسم مضاد ضد CEACAM5 بشري تشتمل على شدفة ذات سلسلة ثقيلة تشتمل على منطقة متغيرة لسلسلة ثقيلة تتكون من سياق الأحماض الأمينية الذي تمثله مواقع الأحماض الأمينية من 1 إلى 121 في السياق برقم تعريف: 2، وسلسلة خفيفة تشتمل على منطقة متغيرة لسلسلة خفيفة تتكون من سياق أحماض أمينية تمثله مواقع الأحماض الأمينية من 1 إلى 112 في السياق برقم تعريف: 4 ومتقارن يشتمل على الشدفة Fab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017133698 | 2017-07-07 | ||
PCT/JP2018/025618 WO2019009388A1 (ja) | 2017-07-07 | 2018-07-06 | 新規な抗ヒトCEACAM5抗体Fabフラグメント |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200002A1 true JOP20200002A1 (ar) | 2020-01-06 |
Family
ID=64950161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0002A JOP20200002A1 (ar) | 2017-07-07 | 2018-07-06 | شدفة Fab جديدة لجسم مضاد ضد CEACAM5 البشري |
Country Status (18)
Country | Link |
---|---|
US (1) | US11667724B2 (ar) |
EP (1) | EP3650470A4 (ar) |
JP (1) | JP7080002B2 (ar) |
KR (1) | KR102665275B1 (ar) |
CN (1) | CN110831977B (ar) |
AU (1) | AU2018296644A1 (ar) |
BR (1) | BR112020000274A2 (ar) |
CA (1) | CA3068691A1 (ar) |
CO (1) | CO2020000517A2 (ar) |
IL (1) | IL271701A (ar) |
JO (1) | JOP20200002A1 (ar) |
MA (1) | MA51029A (ar) |
PH (1) | PH12020500058A1 (ar) |
SG (1) | SG11202000069XA (ar) |
TW (1) | TWI795415B (ar) |
UA (1) | UA126921C2 (ar) |
WO (1) | WO2019009388A1 (ar) |
ZA (1) | ZA202000219B (ar) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019010064A2 (pt) | 2016-11-18 | 2019-10-01 | Astellas Pharma Inc | novo fragmento fab do anticorpo muc1 anti-humano |
TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
JP7374544B2 (ja) * | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物 |
JP2022535553A (ja) * | 2019-06-04 | 2022-08-09 | シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド | 抗ceacam5モノクローナル抗体、その作製方法およびその使用 |
JP2023538114A (ja) | 2020-08-20 | 2023-09-06 | エー2 バイオセラピューティクス, インコーポレイテッド | メソテリン陽性がんを治療するための組成物及び方法 |
IL300497A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Compositions and methods for treating CEACAM-positive cancer |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
EP1174148A4 (en) | 1999-04-28 | 2005-05-04 | Yamanouchi Pharma Co Ltd | PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME |
AU2001249760B2 (en) | 2000-03-30 | 2005-04-21 | Dyax Corp. | Mucin-1 specific binding members and methods of use thereof |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
US7273608B2 (en) * | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
NZ599176A (en) | 2005-08-03 | 2014-04-30 | Immunogen Inc | Immunoconjugate formulations |
EA015860B1 (ru) | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
CA2665356C (en) | 2006-10-04 | 2017-10-31 | Kobenhavns Universitet | Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
WO2010050528A1 (ja) | 2008-10-28 | 2010-05-06 | 塩野義製薬株式会社 | 抗muc1抗体 |
EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
CN101607985B (zh) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体,包含其的组合物,及其用途 |
US8877157B2 (en) | 2009-07-08 | 2014-11-04 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
IN2012DN01663A (ar) | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
IN2012DN01981A (ar) | 2009-09-24 | 2015-07-24 | Gene Techno Science Co Ltd | |
EP2347769A1 (en) | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Cancer stem cell markers and uses thereof |
WO2011135869A1 (ja) | 2010-04-28 | 2011-11-03 | 塩野義製薬株式会社 | 新規なmuc1抗体 |
CN101928347B (zh) * | 2010-05-05 | 2013-03-27 | 上海海抗中医药科技发展有限公司 | 抗癌胚抗原抗体及其应用 |
PT3434346T (pt) | 2010-07-30 | 2020-11-26 | Medimmune Llc | Polipéptidos ou imunoconjugados ativos purificados |
CA2827722C (en) | 2011-03-02 | 2020-05-12 | Roche Glycart Ag | Anti-cea antibodies |
JP6164556B2 (ja) | 2011-12-01 | 2017-07-19 | 国立大学法人 千葉大学 | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 |
KR102408660B1 (ko) * | 2012-11-20 | 2022-06-15 | 사노피 | 항-ceacam5 항체 및 이의 용도 |
ES2673583T3 (es) * | 2013-02-28 | 2018-06-22 | National Cancer Center | Anticuerpo contra fibrina insoluble |
TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
CN105764526B (zh) | 2013-08-26 | 2020-12-15 | 生物技术研发公司 | 编码抗唾液酸化路易斯a抗原的人抗体的核酸 |
TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
KR20160141726A (ko) | 2014-04-07 | 2016-12-09 | 시애틀 지네틱스, 인크. | 항-cd19 항체 및 항체-약물 컨쥬게이트에 대한 안정한 제형 |
AU2015254257B2 (en) | 2014-04-28 | 2021-02-25 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof |
TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
WO2016130726A1 (en) | 2015-02-10 | 2016-08-18 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
EP3424940A4 (en) | 2016-03-01 | 2019-10-30 | National University Corporation Chiba University | RADIOMARCED MEDICINE |
BR112019010064A2 (pt) | 2016-11-18 | 2019-10-01 | Astellas Pharma Inc | novo fragmento fab do anticorpo muc1 anti-humano |
US10758632B2 (en) | 2017-02-06 | 2020-09-01 | City Of Hope | NIR-conjugated tumor-specific antibodies and uses thereof |
TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
EP3689892B1 (en) | 2017-09-26 | 2024-07-17 | National University Corporation Chiba University | Radioactive drug |
BR112020023420A8 (pt) | 2018-05-17 | 2022-06-07 | Astellas Pharma Inc | Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante |
JP7374544B2 (ja) | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物 |
JOP20210180A1 (ar) | 2019-01-07 | 2023-01-30 | Astellas Pharma Inc | مادة اقتران تشتمل على ربيطة، فاصل، رابط ببتيدي وجزيء حيوي |
-
2018
- 2018-07-05 TW TW107123231A patent/TWI795415B/zh active
- 2018-07-06 AU AU2018296644A patent/AU2018296644A1/en active Pending
- 2018-07-06 CN CN201880044520.9A patent/CN110831977B/zh active Active
- 2018-07-06 US US16/628,975 patent/US11667724B2/en active Active
- 2018-07-06 BR BR112020000274-7A patent/BR112020000274A2/pt unknown
- 2018-07-06 KR KR1020197035209A patent/KR102665275B1/ko active IP Right Grant
- 2018-07-06 WO PCT/JP2018/025618 patent/WO2019009388A1/ja unknown
- 2018-07-06 EP EP18827622.4A patent/EP3650470A4/en active Pending
- 2018-07-06 JO JOP/2020/0002A patent/JOP20200002A1/ar unknown
- 2018-07-06 MA MA051029A patent/MA51029A/fr unknown
- 2018-07-06 JP JP2019527977A patent/JP7080002B2/ja active Active
- 2018-07-06 UA UAA202000714A patent/UA126921C2/uk unknown
- 2018-07-06 CA CA3068691A patent/CA3068691A1/en active Pending
- 2018-07-06 SG SG11202000069XA patent/SG11202000069XA/en unknown
-
2019
- 2019-12-25 IL IL271701A patent/IL271701A/en unknown
-
2020
- 2020-01-07 PH PH12020500058A patent/PH12020500058A1/en unknown
- 2020-01-13 ZA ZA2020/00219A patent/ZA202000219B/en unknown
- 2020-01-17 CO CONC2020/0000517A patent/CO2020000517A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA51029A (fr) | 2021-03-24 |
SG11202000069XA (en) | 2020-02-27 |
CN110831977B (zh) | 2023-06-09 |
EP3650470A1 (en) | 2020-05-13 |
BR112020000274A2 (pt) | 2020-07-14 |
CA3068691A1 (en) | 2019-01-10 |
RU2020105654A (ru) | 2021-08-09 |
US20200123270A1 (en) | 2020-04-23 |
KR20200026185A (ko) | 2020-03-10 |
KR102665275B1 (ko) | 2024-05-13 |
EP3650470A4 (en) | 2021-03-24 |
CO2020000517A2 (es) | 2020-01-31 |
UA126921C2 (uk) | 2023-02-22 |
US11667724B2 (en) | 2023-06-06 |
JPWO2019009388A1 (ja) | 2020-05-07 |
TWI795415B (zh) | 2023-03-11 |
AU2018296644A1 (en) | 2020-01-23 |
TW201920273A (zh) | 2019-06-01 |
WO2019009388A1 (ja) | 2019-01-10 |
IL271701A (en) | 2020-02-27 |
ZA202000219B (en) | 2021-08-25 |
JP7080002B2 (ja) | 2022-06-03 |
PH12020500058A1 (en) | 2020-09-28 |
CN110831977A (zh) | 2020-02-21 |
RU2020105654A3 (ar) | 2021-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202000069XA (en) | Novel anti-human ceacam5 antibody fab fragment | |
CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
PH12018502478A1 (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
MX2020008030A (es) | Anticuerpos de glipicano 3 y conjugados de los mismos. | |
PH12015501505A1 (en) | Antibodies that bind to tl1a and their uses | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
JOP20190103B1 (ar) | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري | |
PE20161096A1 (es) | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
MX2010004910A (es) | Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico. | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
AU2015287227A8 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
MX2021002690A (es) | Anticuerpos anti-avb8 y composiciones y usos de los mismos. | |
PH12018502293A1 (en) | Humanized anti-basigin antibodies and the use thereof | |
MX2020003193A (es) | Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos. | |
MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
MX2019004371A (es) | Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos. | |
PH12016501579A1 (en) | Novel anti-presepsin antibody | |
SA521420953B1 (ar) | بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1 |